Recent Research Studies Encouraging Growth of Global Circulating Tumor Cells Prognostic Technologies Market

Growing prevalence of cancer across the world along with the development of therapeutic monitoring is propelling the growth of the global circulating tumor cells (CTCs) prognostic technologies market. The global CTCs prognostic technologies market is expected to take a leap at a CAGR of 26.30% during the period between 2014 and 2020. The overall CTCs prognostic technologies market was worth US$0.43 bn in 2013 and is projected to be valued at US$2.16 bn by 2020. North America is the leading market for CTCs prognostic technologies owing to the increased prevalence of cancer in countries such as the U.S. and the high adoption rate for advanced prognostic technologies. 

Early Detection of CTCs in Prostate Cancer Patients Undergoing Radiation Therapy Helps in Clinical Decision-Making

The global CTCs prognostic technologies market for prostate cancer is likely to register the fastest growth at a CAGR of 25.20% during the period from 2014 to 2020. In 2013, the demand for CTCs prognostic technologies for prostate cancer was the highest. Latest advancements in prognostic technologies have aided the growth of the global CTCs prognostic technologies market. 

According to Nature, a leading weekly international scientific journal, an estimated 233,000 new cases of prostate cancer were diagnosed in the U.S. in 2014. A recent publication in the journal suggests that the presence of CTCs in prostate cancer patients undergoing radiation therapy may be indicative of the disseminated disease. The study detects the presence of CTCs in the blood of prostate cancer patients with the help of CellSearch System (CSS), which has been approved by the U.S. Food and Drug Administration. Assessment of CTCs in the blood of prostate cancer patients undergoing adjuvant and salvage radiation therapy can be helpful in clinical decision-making. Further it also helps evaluating the efficacy of radiation therapy versus other systemic treatments.

Researchers Develop Acoustic System to Detect CTCs

Cancer cells usually migrate from their original locations by circulating through the blood stream and forming new tumors elsewhere in the body. The detection of circulating tumor cells (CTCs) is necessary for the doctors to analyze whether a patient’s tumor will metastasize or how the patient is responding to the treatment. However, detecting these cells is challenging as there might be only one to 10 such cells in a 1 millimeter sample of a patient’s blood. A team of engineers from the Massachusetts Institute of Technology, Carnegie Melon University, and Penn State University have found out a new way to isolate CTCs from patient blood samples. The researchers have developed a new acoustic system that can isolate at least 83% of the cancer cells from samples. The new cell-sorting device can separate CTCs from blood cells by using sound waves which would enable many fundamental research studies and clinical applications. 


Post a Comment

Note: only a member of this blog may post a comment.

Latest Post

Market Research Reports